Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Artery Bypass | 9 | 2013 | 111 | 1.380 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2013 | 81 | 0.690 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2011 | 32 | 0.610 |
Why?
|
| Myocardial Ischemia | 3 | 2011 | 105 | 0.600 |
Why?
|
| Aortic Valve | 3 | 2018 | 60 | 0.530 |
Why?
|
| Coronary Disease | 3 | 2007 | 214 | 0.480 |
Why?
|
| Bioprosthesis | 3 | 2018 | 61 | 0.410 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2018 | 50 | 0.390 |
Why?
|
| Postoperative Hemorrhage | 3 | 2013 | 42 | 0.370 |
Why?
|
| Dexmedetomidine | 1 | 2011 | 8 | 0.360 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2018 | 27 | 0.350 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 29 | 0.350 |
Why?
|
| Propofol | 1 | 2011 | 20 | 0.350 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2010 | 12 | 0.320 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 45 | 0.320 |
Why?
|
| Preoperative Care | 2 | 2008 | 122 | 0.310 |
Why?
|
| Aortic Valve Stenosis | 2 | 2020 | 41 | 0.300 |
Why?
|
| Pulmonary Artery | 2 | 2011 | 25 | 0.290 |
Why?
|
| Heart Diseases | 1 | 2010 | 116 | 0.290 |
Why?
|
| Postoperative Complications | 5 | 2013 | 828 | 0.290 |
Why?
|
| Treatment Outcome | 11 | 2018 | 3438 | 0.280 |
Why?
|
| Ticlopidine | 1 | 2008 | 17 | 0.280 |
Why?
|
| Premedication | 1 | 2008 | 16 | 0.280 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 54 | 0.270 |
Why?
|
| Aged | 18 | 2020 | 10538 | 0.270 |
Why?
|
| Heart Valves | 2 | 2005 | 16 | 0.270 |
Why?
|
| Middle Aged | 18 | 2020 | 12125 | 0.270 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 85 | 0.270 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 29 | 0.260 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 413 | 0.260 |
Why?
|
| Male | 21 | 2020 | 19641 | 0.250 |
Why?
|
| Aprotinin | 1 | 2005 | 4 | 0.240 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2005 | 6 | 0.240 |
Why?
|
| Thymus Neoplasms | 1 | 2005 | 6 | 0.230 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2005 | 13 | 0.230 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 20 | 0.230 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 136 | 0.220 |
Why?
|
| Palliative Care | 1 | 2005 | 51 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 384 | 0.220 |
Why?
|
| Humans | 24 | 2020 | 32798 | 0.220 |
Why?
|
| Female | 18 | 2020 | 20261 | 0.210 |
Why?
|
| Heart Valve Prosthesis | 2 | 2018 | 60 | 0.210 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2004 | 11 | 0.210 |
Why?
|
| Aneurysm, Dissecting | 1 | 2004 | 12 | 0.210 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2003 | 6 | 0.200 |
Why?
|
| Enoxaparin | 1 | 2003 | 21 | 0.200 |
Why?
|
| Hemoglobins | 1 | 2003 | 49 | 0.200 |
Why?
|
| Blood Transfusion | 1 | 2003 | 76 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3701 | 0.190 |
Why?
|
| Risk Factors | 8 | 2018 | 3974 | 0.190 |
Why?
|
| Prognosis | 4 | 2020 | 1544 | 0.190 |
Why?
|
| Time Factors | 5 | 2018 | 2183 | 0.170 |
Why?
|
| Struma Ovarii | 1 | 2019 | 1 | 0.160 |
Why?
|
| Teratoma | 1 | 2019 | 9 | 0.160 |
Why?
|
| Meiosis | 1 | 2019 | 33 | 0.160 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2011 | 56 | 0.150 |
Why?
|
| Adult | 9 | 2020 | 9560 | 0.150 |
Why?
|
| Genome, Human | 1 | 2019 | 132 | 0.150 |
Why?
|
| Carcinoma | 1 | 2019 | 92 | 0.150 |
Why?
|
| Echocardiography | 1 | 2020 | 182 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 103 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 162 | 0.150 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 51 | 0.140 |
Why?
|
| Ventricular Function, Left | 4 | 2020 | 252 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 30 | 0.130 |
Why?
|
| Femoral Artery | 1 | 2017 | 50 | 0.130 |
Why?
|
| Stents | 1 | 2018 | 174 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 92 | 0.130 |
Why?
|
| Survival Rate | 3 | 2010 | 894 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 4032 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 271 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2020 | 486 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2004 | 58 | 0.100 |
Why?
|
| Cognition Disorders | 2 | 2007 | 370 | 0.100 |
Why?
|
| Factor IX | 1 | 2013 | 11 | 0.100 |
Why?
|
| North Carolina | 2 | 2010 | 1546 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2010 | 1460 | 0.100 |
Why?
|
| Heparin | 2 | 2003 | 70 | 0.100 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2011 | 8 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 881 | 0.090 |
Why?
|
| Probability | 3 | 2009 | 157 | 0.080 |
Why?
|
| Critical Care | 1 | 2011 | 108 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2009 | 185 | 0.080 |
Why?
|
| Swine | 2 | 2009 | 216 | 0.080 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2007 | 6 | 0.080 |
Why?
|
| Exercise Test | 1 | 2010 | 223 | 0.080 |
Why?
|
| Ranitidine | 1 | 2009 | 2 | 0.080 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 2 | 0.080 |
Why?
|
| Peptic Ulcer | 1 | 2009 | 4 | 0.080 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2009 | 8 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2011 | 876 | 0.070 |
Why?
|
| Bioreactors | 1 | 2009 | 61 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 252 | 0.070 |
Why?
|
| Pericarditis, Constrictive | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cross Infection | 1 | 2009 | 56 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 576 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2008 | 48 | 0.070 |
Why?
|
| Blood Volume | 1 | 2008 | 9 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2010 | 381 | 0.070 |
Why?
|
| Platelet Transfusion | 1 | 2008 | 16 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 682 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 1 | 2008 | 36 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 197 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 767 | 0.070 |
Why?
|
| Reoperation | 2 | 2011 | 260 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2008 | 2327 | 0.070 |
Why?
|
| Logistic Models | 2 | 2009 | 783 | 0.070 |
Why?
|
| Saphenous Vein | 1 | 2007 | 20 | 0.070 |
Why?
|
| Prevalence | 1 | 2010 | 1002 | 0.060 |
Why?
|
| Animals | 3 | 2009 | 7569 | 0.060 |
Why?
|
| Incidence | 2 | 2009 | 1238 | 0.060 |
Why?
|
| Age Factors | 2 | 2007 | 1197 | 0.060 |
Why?
|
| Hematocrit | 1 | 2005 | 23 | 0.060 |
Why?
|
| Causality | 1 | 2005 | 39 | 0.060 |
Why?
|
| Thymectomy | 1 | 2005 | 3 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 78 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 82 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 11 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 90 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 289 | 0.060 |
Why?
|
| Cattle | 1 | 2004 | 108 | 0.050 |
Why?
|
| Polyethylene Terephthalates | 1 | 2004 | 3 | 0.050 |
Why?
|
| Pericardium | 1 | 2004 | 55 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 116 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 470 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 497 | 0.050 |
Why?
|
| Comorbidity | 1 | 2005 | 573 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2284 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2007 | 908 | 0.050 |
Why?
|
| Suture Techniques | 1 | 2004 | 61 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2009 | 659 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 68 | 0.050 |
Why?
|
| Pipecolic Acids | 1 | 2003 | 6 | 0.050 |
Why?
|
| Sepsis | 1 | 2005 | 165 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 28 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 97 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 59 | 0.050 |
Why?
|
| Disease Progression | 1 | 2005 | 594 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 168 | 0.050 |
Why?
|
| Hemodynamics | 2 | 2018 | 162 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 422 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2003 | 136 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 622 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 428 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2013 | 1844 | 0.040 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 7 | 0.040 |
Why?
|
| Homozygote | 1 | 2019 | 58 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 27 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 65 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 19 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 647 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 154 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 33 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2018 | 102 | 0.040 |
Why?
|
| Punctures | 1 | 2017 | 36 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 203 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 1140 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2020 | 370 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 329 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 369 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 204 | 0.030 |
Why?
|
| Chest Tubes | 1 | 2013 | 5 | 0.030 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2013 | 4 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2013 | 13 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 16 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 247 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2011 | 95 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 3 | 0.020 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2009 | 15 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 92 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 126 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 96 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 148 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 238 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 201 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 694 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 233 | 0.020 |
Why?
|
| Diastole | 1 | 2008 | 97 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2008 | 27 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 115 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2007 | 25 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1083 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1282 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 764 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 363 | 0.020 |
Why?
|
| Constriction | 1 | 2005 | 13 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2005 | 85 | 0.010 |
Why?
|
| Epinephrine | 1 | 2005 | 40 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 43 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 59 | 0.010 |
Why?
|
| Dobutamine | 1 | 2005 | 55 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2003 | 22 | 0.010 |
Why?
|
| Aorta | 1 | 2003 | 127 | 0.010 |
Why?
|
| Dopamine | 1 | 2005 | 234 | 0.010 |
Why?
|
| Critical Illness | 1 | 2003 | 84 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 511 | 0.010 |
Why?
|